Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study

Ann Rheum Dis. 2024 Apr 11;83(5):680-682. doi: 10.1136/ard-2023-225162.

Abigail E Schiff^{1

2}, Xiaosong Wang^{1

3}, Naomi J Patel^{2

4}, Yumeko Kawano^{1

2

3}, Jennifer L Hanberg^{1

2

3}, Emily N Kowalski^{1

3}, Claire E Cook⁴, Kathleen Mm Vanni^{1

3}, Grace Qian^{1

3}, Katarina J Bade^{1

3}, Alene A Saavedra^{1

3}, Shruthi Srivatsan⁴, Zachary K Williams⁴, Rathnam K Venkat⁵, Zachary S Wallace^#^{2

4}, Jeffrey A Sparks^#^{6

3}

¹ Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
² Harvard Medical School, Boston, Massachusetts, USA.
³ Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
⁴ Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁵ Tufts Medical Center, Boston, Massachusetts, USA.
⁶ Harvard Medical School, Boston, Massachusetts, USA jsparks@bwh.harvard.edu.

^# Contributed equally.

No abstract available

Keywords: Arthritis, Rheumatoid; Covid-19; Epidemiology; Rituximab; Vaccination.

Publication types